- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
All News
Mirvetuximab Elicits Responses in More Than 31% of Patients With FRα-High Platinum-Resistant Ovarian Cancer
November 30, 2021
Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.
New CDK9 Inhibitor Shows Favorable Pharmacokinetic Profile in MYC-Amplified Solid Tumors
November 30, 2021
KB-0742 is currently being evaluated in a phase 1/2 clinical trial. The terminal half-life was found to be 24 hours.
FDA Grants Priority Review to Olaparib for Adjuvant Treatment BRCA-mutated HER2- High-Risk eBC
November 30, 2021
Findings from the phase 3 OlympiA led to the filing of a supplemental new drug application for olaparib as adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer.
Frontline car-BIRD Regimen Shows Potential for Patients With Multiple Myeloma
November 30, 2021
In an interview with Targeted Oncology, Ruben Niesvizky, MD, discussed current efficacy outcomes in multiple myeloma and how the introduction of the car-BIRD regimen may improve upon them.
The Potential of Rebastinib in Platinum-Resistant Ovarian Cancer Treatment
November 29, 2021
Erika Hamilton, MD, discusses the mechanism of action of rebastinib, which is currently being explored in combination with weekly paclitaxel 1b/2 study of patients with platinum-resistant ovarian cancer.
ICU Admission, Oxygen Use Predict Outcomes in Patients With Cancer and COVID-19
November 29, 2021
Markus Joerger, MD, discussed the outcomes and prognostic factors of patients with cancer won contract COVID-19 in an interview with Targeted Oncology.
Novel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer
November 29, 2021
Efficacy signals have been shown in 100% of patients with metastatic prostate cancer treated with a new formulation of cabazitaxel.
FDA 'Fast Tracks' Arfolitixorin for Metastatic Colorectal Cancer
November 29, 2021
After 40 years, a novel agent may be on the fast track to becoming the first drug to improve the standard of care for patients with metastatic colorectal cancer.
Investigators Dose Datopotamab Deruxtecan in First Patient With HR+ /HER2- Breast Cancer
November 26, 2021
The TROPION-Breast01 study aims to enroll 700 patients to determine the safety and efficacy of datopotamab deruxtecan in patients with HR-positive, HER2-negative breast cancer.
FDA Grants Orphan Drug Designation to Novel CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
November 26, 2021
A novel chimeric antigen receptor T-cell agent will now be developed in the United States following an orphan drug designation granted by the FDA.